5 recruiting, 1 completed. 4 Phase 3, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 4 | Recruiting 4 |
| Phase 2 | 2 | Completed 1, Recruiting 1 |
Follow NBI-1117568: new trials by email Literature Review of NBI-1117568 trials Research Report on NBI-1117568
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| An Assessment of Efficacy, Safety, and Pharmacokinetics of NBI-1117568 in Adults With Bipolar I Disorder With Current Mania NBI-1117568, Placebo - Bipolar I Disorder, Mania | Phase 2 | Recruiting | Neurocrine Biosciences | 150 | 2025-12-24 | 2026-09-29 |
| Efficacy of NBI-1117568 in Preventing Relapse in Adults With Schizophrenia NBI-1117568, Placebo - Schizophrenia | Phase 3 | Recruiting | Neurocrine Biosciences | 560 | 2025-12-16 | 2026-09-25 |
| NBI-1117568-SCZ3030: Evaluation of NBI-1117568 in Inpatient Adults With Schizophrenia NBI-1117568, Placebo - Schizophrenia | Phase 3 | Recruiting | Neurocrine Biosciences | 284 | 2025-08-11 | 2026-09-25 |
| NBI-1117568-SCZ3032: Long-Term Evaluation of NBI-1117568 in Adults With Schizophrenia NBI-1117568 - Schizophrenia | Phase 3 | Recruiting | Neurocrine Biosciences | 600 | 2025-07-11 | 2026-09-25 |
| NBI-1117568-SCZ3029: Evaluation of NBI-1117568 in Inpatient Adults With Schizophrenia NBI-1117568, Placebo - Schizophrenia | Phase 3 | Recruiting | Neurocrine Biosciences | 284 | 2025-05-08 | 2026-03-06 |
| Efficacy, Safety, Tolerability, and Pharmacokinetics of NBI-1117568 in Adults With Schizophrenia NBI-1117568, Placebo - Schizophrenia | Phase 2 | Completed | Neurocrine Biosciences | 210 | 2022-10-04 | 2025-07-11 |
Schizophrenia (5) · Mania (1)
United States (6) · Serbia (3) · Bulgaria (2) · Puerto Rico (2) · Romania (2) · Hungary (1)
2025 (2)